The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.
Wolfgang Wick
Consultant or Advisory Role - Apogenix (U); MSD; Roche
Research Funding - Apogenix; MSD; Roche
Thierry Gorlia
No relevant relationships to disclose
Martin J. Van Den Bent
No relevant relationships to disclose
Charles J Vecht
No relevant relationships to disclose
Jonathan Steuve
No relevant relationships to disclose
Alba Ariela Brandes
No relevant relationships to disclose
Michael Platten
No relevant relationships to disclose
Markus A Kosch
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Monika E. Hegi
No relevant relationships to disclose
Benoit Lhermitte
No relevant relationships to disclose
Vassilis Golfinopoulos
No relevant relationships to disclose
Mario Campone
No relevant relationships to disclose
Jean-Sebastien Frenel
No relevant relationships to disclose
Martin J.B. Taphoorn
No relevant relationships to disclose
Gianfranco A. Pesce
No relevant relationships to disclose
Patrick Roth
No relevant relationships to disclose